<DOC>
	<DOCNO>NCT00091819</DOCNO>
	<brief_summary>Study 0017 compare safety effectiveness investigational drug , telavancin , approve drug , vancomycin , treatment complicate skin skin structure infection .</brief_summary>
	<brief_title>Comparison Telavancin Vancomycin Complicated Skin Skin Structure Infections With Focus Methicillin-resistant Staphylococcus Aureus</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Staphylococcal Skin Infections</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<mesh_term>Telavancin</mesh_term>
	<criteria>Patients must diagnosis one follow complicate skin skin structure infection Methicillin Resistant Staphylococcus aureus ( MRSA ) either suspect confirmed major cause infection : major abscess require surgical incision drainage infect burn ( see exclusion criterion important qualification ) deep/extensive cellulitis infect ulcer ( see exclusion criterion important qualification ) wind infection Patients must expect require least 7 day intravenous antibiotic treatment Received 24 hour potentially effective systemic ( IV , IM PO ) antibiotic therapy prior randomization Burns involve &gt; 20 % body surface area thirddegree/fullthickness nature , diabetic foot ulcer , ischemic ulcers/wounds , necrotizing fascitis , gas gangrene , mediastinitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>staph</keyword>
	<keyword>MRSA</keyword>
	<keyword>cSSSI</keyword>
</DOC>